Osamu Ishikawa
Overview
Explore the profile of Osamu Ishikawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
554
Citations
6479
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yasuda M, Sasahira S, Okada E, Tamura A, Ishikawa O, Goto K, et al.
J Dermatol
. 2025 Jan;
PMID: 39835403
No abstract available.
2.
Ishii T, Kawaguchi Y, Ishikawa O, Takemori H, Takasawa N, Kobayashi H, et al.
Mod Rheumatol
. 2024 Nov;
PMID: 39562303
Objectives: Systemic sclerosis is characterised by ischaemic skin ulcers on the fingertips, and low-energy shock wave therapy is suggested as a novel treatment for ischaemic lesions with angiogenic effects. We...
3.
Khanna D, Kramer F, Hofler J, Ghadessi M, Sandner P, Allanore Y, et al.
Rheumatology (Oxford)
. 2024 Mar;
63(11):3124-3134.
PMID: 38460548
Objective: To examine disease and target engagement biomarkers in the RISE-SSc trial of riociguat in early diffuse cutaneous systemic sclerosis and their potential to predict the response to treatment. Methods:...
4.
Ishikawa Y, Tanaka N, Asano Y, Kodera M, Shirai Y, Akahoshi M, et al.
Nat Commun
. 2024 Jan;
15(1):319.
PMID: 38296975
Here we report the largest Asian genome-wide association study (GWAS) for systemic sclerosis performed to date, based on data from Japanese subjects and comprising of 1428 cases and 112,599 controls....
5.
Distler O, Allanore Y, Denton C, Kuwana M, Matucci-Cerinic M, Pope J, et al.
Lancet Rheumatol
. 2024 Jan;
5(11):e660-e669.
PMID: 38251533
Background: The phase 2b Riociguat Safety and Efficacy in Patients with Diffuse Cutaneous Systemic Sclerosis (RISE-SSc) trial investigated riociguat versus placebo in early diffuse cutaneous systemic sclerosis. The long-term extension...
6.
Hirano Y, Koizumi S, Shojima M, Ishikawa O, Kiyofuji S, Umekawa M, et al.
Surg Neurol Int
. 2023 Sep;
14:273.
PMID: 37680911
Background: Recurrent cerebral aneurysms have complex shapes and are often technically challenging to treat with a single microcatheter. This study evaluates the clinical characteristics and treatment outcomes of patients who...
7.
Sakai Y, Yoshikawa G, Koizumi S, Ishikawa O, Saito A, Sato K
J Neuroendovasc Ther
. 2023 Jul;
17(1):15-21.
PMID: 37501883
Objective: There are insufficient coherent reports on mechanical thrombectomy (MT) for occlusion of the second segment of the middle cerebral artery (M2 occlusion) in a real-world clinical setting. We evaluated...
8.
Takahashi H, Akita H, Wada H, Miyata H, Eguchi H, Ohigashi H, et al.
Ann Surg
. 2023 Apr;
278(6):e1216-e1223.
PMID: 37057622
Objective: To investigate the long-term dynamics of recurrence risk and the significance of prognostic variables using conditional recurrence-free survival (C-RFS) analysis in neoadjuvant treatment (NAT) for resectable (R) and borderline...
9.
Hasegawa S, Takahashi H, Akita H, Mukai Y, Mikamori M, Asukai K, et al.
BMC Cancer
. 2023 Jan;
23(1):63.
PMID: 36653747
Background: Duke pancreatic mono-clonal antigen type 2 (DUPAN-II) is a famous tumour maker for pancreatic cancer (PC) as well as carbohydrate antigen 19-9 (CA19-9). We evaluated the clinical implications of...
10.
Yasuda M, Shang C, Yamanaka M, Amano H, Tsukamoto N, Ishikawa O, et al.
J Dermatol
. 2022 Nov;
50(3):e106-e107.
PMID: 36353784
No abstract available.